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SUMMARY

The endocannabinoid 2-arachidonoylglycerol (2-AG)
is a retrograde lipid messenger that modulates synaptic function, neurophysiology, and behavior. 2-AG
signaling is terminated by enzymatic hydrolysis—a
reaction that is principally performed by monoacylglycerol lipase (MAGL). MAGL is broadly expressed
throughout the nervous system, and the contributions of different brain cell types to the regulation of
2-AG activity in vivo remain poorly understood.
Here, we genetically dissect the cellular anatomy of
MAGL-mediated 2-AG metabolism in the brain and
show that neurons and astrocytes coordinately regulate 2-AG content and endocannabinoid-dependent
forms of synaptic plasticity and behavior. We also
find that astrocytic MAGL is mainly responsible for
converting 2-AG to neuroinflammatory prostaglandins via a mechanism that may involve transcellular
shuttling of lipid substrates. Astrocytic-neuronal
interplay thus provides distributed oversight of
2-AG metabolism and function and, through doing
so, protects the nervous system from excessive
CB1 receptor activation and promotes endocannabinoid crosstalk with other lipid transmitter systems.
INTRODUCTION
Historical neuron-centric conceptualizations of brain function
have given way to a deeper appreciation of the important roles
played by additional brain cell types in regulating chemical transmission throughout the nervous system (McIver et al., 2013).
Astrocytes are now recognized as integral components of synapses and central regulators of neurotransmission and interneuronal communication (Halassa and Haydon, 2010). Astroglial
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transporters clear neurotransmitters, such as glutamate and
g-amino butyric acid (GABA), from synaptic clefts to modulate
the signaling activities of these chemical messengers and limit
their toxic accumulation in the extracellular space (Danbolt,
2001). Metabolic pathways in astrocytes are also essential for
the recycling and resupply of neurotransmitters needed to maintain sustained rounds of synaptic activity (Coulter and Eid, 2012).
Moreover, defects in astrocytic functions that lead to alterations
in the homeostasis of major neurotransmitters have been linked
to a variety of mental and neurodegenerative disorders (Allaman
et al., 2011; Halassa and Haydon, 2010). Microglia, which are
resident immune cells of the nervous system, also contribute
to neurotransmission through activity-dependent remodeling
and pruning of synapses (Salter and Beggs, 2014; Schafer
et al., 2012). Efforts to elucidate the contributions of glia to the
regulation of synaptic function therefore stand to both enrich
our mechanistic understanding of intercellular communication
in the brain and provide new therapeutic avenues for the treatment of diverse neurological conditions.
The endogenous cannabinoid (endocannabinoid or eCB)
2-arachidonoylglycerol (2-AG) is an arachidonic acid (AA)derived retrograde lipid messenger that broadly modulates
synaptic function throughout the nervous system (Fowler et al.,
2005; Kano et al., 2009; Pacher et al., 2006). 2-AG is synthesized
by diacylglycerol lipases (DAGLs) (Reisenberg et al., 2012) and
released in an activity-dependent manner from postsynaptic
neurons to act on presynaptic G-protein-coupled cannabinoid
receptors CB1 (CB1R) and CB2, which are also targets of the
primary psychoactive component of marijuana (D9-tetrahydrocannabinol) (Mechoulam and Hanus, 2000). Principally through
its activity on CB1Rs, 2-AG inhibits neurotransmitter release
and regulates diverse neurophysiological processes, including
mood, nociception, appetite, and memory (Pacher et al.,
2006). Enzymatic hydrolysis of 2-AG, which is primarily mediated
by monoacylglycerol lipase (MAGL) in the nervous system (Dinh
et al., 2002; Ueda et al., 2013), terminates CB1R-dependent
signaling (Chanda et al., 2010; Schlosburg et al., 2010; Zhong
et al., 2011) and concomitantly provides a major source of AA

for brain eicosanoid synthesis (Nomura et al., 2011). The DAGL
and MAGL enzymes thus tightly regulate 2-AG-mediated neurotransmission and have historically been viewed as doing so
through their respective expression in the pre- and post-synaptic
compartments of neurons (Di Marzo et al., 2015). Glial cells may
also serve as cellular substrates for the modulation of 2-AG,
however, as both astrocytes and microglia release this eCB
and express CB1Rs (Navarrete and Araque, 2008, 2010; Stella,
2010; Walter et al., 2004; Witting et al., 2004). Furthermore,
ectopic expression of MAGL in Bergmann glia has been shown
to attenuate 2-AG-dependent retrograde synaptic suppression
in cerebellar slices from MAGL / mice (Tanimura et al., 2012).
Nonetheless, the relative contributions of neurons and glia to
the termination of 2-AG-dependent synaptic and neurobehavioral functions, as well as the potential for crosstalk between these
cell types to facilitate the recycling and homeostasis of eCBeicosanoid pools, remain largely unexplored.
Global pharmacological or genetic disruption of MAGL
robustly elevates brain 2-AG content (Chanda et al., 2010;
Long et al., 2009; Schlosburg et al., 2010), alters CB1R-mediated
signaling and behaviors (Chanda et al., 2010; Long et al., 2009;
Schlosburg et al., 2010; Zhong et al., 2011), and impairs neuroinflammation through mechanisms that involve eCB-eicosanoid
crosstalk (Nomura et al., 2011). With the goal of determining the
relative contribution of different brain cell types to 2-AG metabolism and signaling in vivo, we report the generation and characterization of a conditional genetic mouse model used to ablate
MAGL globally and specifically in neurons, astrocytes, and microglia. We discover that neuronal and astrocytic MAGL coordinately regulate brain 2-AG content, contribute to the termination
of synaptic 2-AG signaling at CB1Rs, and, by doing so, maintain
a balanced eCB tone that protects against desensitization
caused by excessive signaling. Moreover, we show that
astrocytic MAGL is principally responsible for generating
2-AG-derived arachidonate pools used for the synthesis of
pro-inflammatory prostaglandins in the brain. Finally, we provide
evidence for the transcellular shuttling of 2-AG and related metabolites between neurons and astrocytes as one mechanism
by which these cells can coordinately regulate eCB-eicosanoid
pathways in the nervous system. The distributed metabolism
of 2-AG across both neurons and astrocytes thus affords the
nervous system more refined control over dynamic features
of eCB activity, including protection against desensitization
and facilitating crosstalk with other lipid transmitter systems
that are deregulated in disease states.
RESULTS
Cell-Type-Specific Deletion of MAGL in the Nervous
System
To examine the contribution of different brain cell types to 2-AG
metabolism and signaling in vivo, we generated a genetic mouse
model for conditional deletion of the MAGL enzyme by flanking the
catalytic exon of the Mgll gene (exon 4, containing catalytic S122)
with loxP recombination sites (MAGLloxP, Figures 1A and S1A–
S1C). The MAGLloxP line was initially validated by crossing to
mice that ubiquitously express Cre recombinase (Rosa26-Cre;
Otto et al., 2009) to produce total MAGL / mice (MAGL-TKO).

Consistent with previous reports for other conventional MAGL /
lines (Chanda et al., 2010; Schlosburg et al., 2010), MAGL-TKO
mice lacked detectable MAGL expression and activity across
different central and peripheral tissues and cell types (Figures
1B–1E and S1D). MAGL-TKO mice also exhibited marked
(90%) reductions in brain 2-AG hydrolysis (Figure 1F), as well
as 10-fold elevations in brain 2-AG content (Figure 1G).
We next crossed homozygous MAGLloxP mice to mice with
restricted expression of Cre recombinase in neurons (Eno2-Cre;
Frugier et al., 2000), astrocytes (GFAP-Cre; Tao et al., 2011), or
microglia (LysM-Cre; Clausen et al., 1999) to generate mouse
lines that lack MAGL specifically in these three brain cell
types (MAGL-NKO, MAGL-AKO, and MAGL-MKO, respectively).
Crossing of Eno2-, GFAP-, and LysM-cre mice to a Cre-inducible
Rosa26-tdTomato reporter line validated efficient Cre-mediated
recombination throughout the brain of these animals, selectively
in neurons, astrocytes, and microglia, respectively (Figure S1E).
While the Eno2- and GFAP-Cre lines produced Cre-mediated
recombination in the vast majority (80–90+%) of neurons and
astrocytes, respectively (with the GFAP-Cre line also showing
low-level (2%–6%) recombination in neurons, consistent with
previous studies; Tao et al., 2011), the LysM-Cre line only appeared to promote Cre-mediated recombination in 50%–60%
of Iba1-positive microglia in the brain. Cultured preparations of
brain cells (Figure S1F and S1G), however, confirmed selective
and near-complete loss of MAGL expression in microglia from
MAGL-MKO mice, as well as in neurons (GABAergic and glutamatergic; Figure S1H) and astrocytes from MAGL-NKO and MAGLAKO, respectively (Figure 1B). Importantly, each MAGL-disrupted
brain cell type also displayed significantly reduced 2-AG hydrolytic activity, although the relative magnitude of this decrease
was greater for neurons compared to astrocytes or microglia,
possibly due to the presence of additional 2-AG hydrolases in
glia (Marrs et al., 2010; Figure 1C).
Having established mouse models that display selective loss of
MAGL in different brain cell types, we next examined how neurons, astrocytes, and microglia contribute to bulk 2-AG metabolism in the nervous system. Deletion of MAGL in both neurons
and astrocytes, but not microglia, substantially reduced the total
quantity of active enzyme in brain tissue, as measured by activitybased protein profiling (ABPP; Figures 1D and 1E). These data
mirrored the effects on brain 2-AG hydrolysis, which was
decreased by 60% and 40% in MAGL-NKO and MAGL-AKO
mice, respectively, but unaltered in MAGL-MKO mice (Figure 1F).
Notably, both MAGL-NKO and MAGL-AKO mice displayed significant (5- and 3-fold, respectively) increases in brain 2-AG
(Figure 1G). No changes in brain 2-AG content were found in
MAGL-MKO mice. Finally, none of the conditional MAGL /
mouse lines displayed alterations in anandamide (AEA) (Figure 1H), a second major eCB that is principally hydrolyzed by fatty
acid amide hydrolase (Cravatt et al., 1996). These data, taken
together, indicate that both neuronal and astrocytic MAGL
make substantial contributions to 2-AG metabolism in the brain.
Neuronal and Astrocytic MAGL Regulate
eCB-Dependent Synaptic Plasticity
2-AG functions as a major retrograde synaptic messenger that
suppresses neurotransmitter release after binding to presynaptic
Cell Reports 12, 798–808, August 4, 2015 ª2015 The Authors 799

Figure 1. Brain Cell Type-Specific Deletion
of MAGL Identifies Both Neurons and Astrocytes as Key Regulators of 2-AG Metabolism in the Nervous System
(A) Diagram of the targeted Mgll locus in MAGLloxP
mice, in which the catalytic exon 4 of this enzyme
is flanked by loxP recombination sites (GHSMG
sequence containing the catalytic serine nucleophile is shown). When MAGLloxP mice are crossed
with mice that express Cre recombinase, exon 4 is
excised to produce the null allele (MAGL ).
(B) Western blot of neurons, astrocytes, and
microglia derived from MAGL-TKO (T, total),
MAGL-NKO (N, neuron), MAGL-AKO (A, astrocyte), or MAGL-MKO (M, microglia) mice confirms
efficient and cell-type-specific depletion of MAGL
in these different mouse lines.
(C) 2-AG hydrolytic activities of neuron, astrocyte,
and microglia membrane proteomes derived from
MAGL-TKO (T), MAGL-NKO (N), MAGL-AKO (A),
and MAGL-MKO (M) mice confirms cell-typespecific loss of MAGL in these different mice. n =
4–5 per cell type and genotype. Error bars represent SEM; **p < 0.01 versus MAGL+/+ samples.
(D and E) SDS-PAGE readout of an activity-based
protein profiling (ABPP) analysis of brain membrane proteomes from MAGL-TKO (T), MAGLNKO (N), MAGL-AKO (A), and MAGL-MKO (M)
mice using a serine-hydrolase-directed fluorophosphonate-rhodamine probe (Cravatt et al.,
2008) (fluorescent gel shown in grayscale) (D).
Quantification of MAGL band intensity is shown
(E). n = 4–5 mice per genotype. Error bars represent SEM; **p < 0.01 versus MAGL+/+ samples.
(F) 2-AG hydrolytic activities of MAGL-TKO (T),
MAGL-NKO (N), MAGL-AKO (A), and MAGL-MKO
(M) brain membrane proteomes. n = 4–5 mice per
genotype. Error bars represent SEM; **p < 0.01
versus MAGL+/+ samples.
(G and H) Brain levels of 2-AG (G) and anandamide
(AEA, H) in MAGL-TKO (T), MAGL-NKO (N),
MAGL-AKO (A), and MAGL-MKO (M) mice. n = 8
mice per genotype. Error bars represent SEM;
**p < 0.01 versus MAGL+/+ samples.
See also Figure S1.

CB1Rs (Kano et al., 2009). Various forms of synaptic plasticity are
regulated by retrograde eCB signaling, including depolarizationinduced suppression of excitation (DSE) and inhibition (DSI)
(Kano et al., 2009). Complete genetic or pharmacological ablation of MAGL activity significantly prolongs DSE/DSI (Pan et al.,
2009; Straiker et al., 2009; Zhong et al., 2011), and the selective
ablation of MAGL in cerebellar granule cells also extends DSE,
but to a lesser degree than global ablation of the enzyme (Tanimura et al., 2012). To more clearly delineate the relative control
that different brain cell types exert over 2-AG-dependent forms
of synaptic plasticity, we initially examined DSE at parallel fiber
(PF) to Purkinje cell (PC) synapses in acute cerebellar slices prepared from the different conditional MAGL-knockout lines.
A brief depolarization of PCs induced robust transient DSE at
PF-PC synapses in MAGL+/+ cerebellar slices (Figures 2A–2C).
Consistent with previous reports (Tanimura et al., 2012; Zhong
et al., 2011), global deletion of MAGL substantially prolonged
the duration (Figure 2A), but not magnitude (Figure S2A), of
800 Cell Reports 12, 798–808, August 4, 2015 ª2015 The Authors

DSE at PF-PC synapses in MAGL-TKO mice. A less dramatic
but significant DSE extension was also observed in cerebellar
slices from MAGL-NKO mice (Figure 2B). Notably, cerebellar
slices from MAGL-AKO mice also showed a significant prolongation in DSE (Figure 2C) that was nearly identical in total
duration to that observed in MAGL-NKO slices, as indicated
by changes in the mean decay time constant (t) (Figure 2D).
No differences in DSE were evident in MAGL-MKO mice
(Figure S2B).
We further examined the contributions of neurons and astrocytes to CB1R-mediated forms of synaptic plasticity by assessing DSI at CA1 pyramidal neuron synapses in hippocampal slices
prepared from MAGL-TKO, MAGL-NKO, and MAGL-AKO, mice,
as well as their wild-type littermates. DSI was readily induced in
MAGL+/+ CA1 pyramidal neurons by applying a brief depolarization while evoking inhibitory postsynaptic currents (IPSCs)
through stimulation of synaptic inhibitory inputs (see Experimental Procedures; Figures 2E–2G). Consistent with previous

Figure 2. Astrocytic and Neuronal MAGL
Play Complementary Roles in Terminating
Retrograde 2-AG Signaling
(A–C) Average time courses of PF-EPSCs in
response to a brief depolarization in cerebellar
slices prepared from MAGL-TKO (A), MAGL-NKO
(B), and MAGL-AKO (C) mice and their wild-type
littermates show prolonged DSE following global,
neuron- or astrocyte-specific loss of MAGL.
Sample traces are shown for MAGL-TKO mice.
n = 14–18 cells from n = 3 mice per genotype.
(D) Time constant (t) of DSE in cerebellar slices
prepared from MAGL-TKO (T), MAGL-NKO (N),
and MAGL-AKO (A) mice and their wild-type littermates. n = 14–18 cells from n = 3 mice per
genotype. Error bars represent SEM; *p < 0.05,
**p < 0.01, ***p < 0.001 versus MAGL+/+.
(E–G) Average time courses of IPSCs in CA1
pyramidal neurons in response to a brief depolarization in hippocampal slices prepared from
MAGL-TKO (E), MAGL-NKO (F), and MAGL-AKO
(G) mice and their wild-type littermates show
prolonged DSI following global, neuron- or astrocyte-specific loss of MAGL. Sample traces are
shown for MAGL-TKO mice. n = 13–15 cells from
n = 3 mice per genotype.
(H) Time constant (t) of DSI in hippocampal slices
prepared from MAGL-TKO (T), MAGL-NKO (N),
and MAGL-AKO (A) mice and their wild-type
littermates. n = 13–15 cells from n = 3 mice per
genotype. Error bars represent SEM; *p < 0.05,
**p < 0.01 versus MAGL+/+.
See also Figure S2.

reports (Pan et al., 2011), the duration of hippocampal DSI in
MAGL-TKO mice was substantially prolonged (Figure 2E). Significant, albeit less dramatic, extensions in DSI were also observed
in hippocampal slices from MAGL-NKO and MAGL-AKO mice
(Figures 2F and 2G), both of which displayed similar increases
in t (Figure 2H).
These findings, taken together, indicate that astrocytes and
neurons both play prominent roles in terminating 2-AG signaling
at synaptic terminals, and, as a result, dramatic increases in the
duration of CB1R activation are only observed when MAGL is
deleted from both brain cell types.

Neuronal and Astrocytic MAGL
Regulate Functional CB1R
Adaptations In Vivo
Chronic, global inactivation of MAGL,
achieved by either genetic disruption
or repeated treatment with a MAGL
inhibitor, has been shown to produce
behavioral tolerance in pain models,
cross-tolerance to exogenous cannabinoids, and desensitization and downregulation of brain CB1Rs (Chanda et al.,
2010; Schlosburg et al., 2010). In agreement with these earlier reports, we found
that the antinociceptive and hypothermic
effects of the CB1R agonist WIN55,212-2
were substantially attenuated in MAGL-TKO mice compared to
their wild-type littermates (Figures 3A and 3B). No evidence of
cross-tolerance to WIN55,212-2 was observed in either MAGLNKO or MAGL-AKO mice (Figures 3C–3F). Correlating with these
behavioral data, MAGL-TKO mice, but not MAGL-NKO or
MAGL-AKO mice, showed a dramatic reduction in brain CB1R
function, as measured by CB1R agonist (CP55,940)-stimulated
[35S]-GTPgS binding (Figures 3G–3I). These results indicate
that expression of MAGL in either neurons or astrocytes is sufficient to prevent excessive activation and corresponding desensitization of brain CB1Rs in vivo, highlighting the contribution that
Cell Reports 12, 798–808, August 4, 2015 ª2015 The Authors 801

Figure 3. Astrocytic and Neuronal MAGL Maintain a Balanced eCB
Tone to Protect against CB1R Desensitization
(A–F) Antinociceptive and hypothermic effects of full CB1R agonist
WIN55,212-2 in MAGL-disrupted mice. MAGL-TKOs (A and B), but not MAGLNKO (C and D) or MAGL-AKOs (E and F), display significant cross-tolerance to
WIN55,212-2-induced antinociception and hypothermia. n = 7–8 mice per
group. Error bars represent SEM; *p < 0.05 and **p < 0.01 versus wild-type
littermates.
(G–I) CP55,940-stimulated [35S]-GTPgS binding in hippocampal homogenates
from MAGL-TKO, MAGL-NKO, and MAGL-AKO mice presented as concentration-effect curves (G) and Emax (H) or EC50 (I) values determined by nonlinear regression. n = 5 mice per group assayed in triplicate. Error bars
represent SEM; **p < 0.01 versus MAGL+/+ samples.

both cell types make to 2-AG metabolism and the maintenance
of eCB signaling tone.
Astrocytes Are Critical Mediators of eCB-Eicosanoid
Crosstalk
MAGL serves as a metabolic hub linking eCB and eicosanoid
signaling pathways in the brain, where the hydrolysis of 2-AG
provides a major source of AA substrate for prostaglandin
synthesis (Nomura et al., 2011). MAGL blockade has been
shown to coordinately elevate 2-AG and lower eicosanoid con802 Cell Reports 12, 798–808, August 4, 2015 ª2015 The Authors

tent in the nervous system under basal and neuroinflammatory
states, including in disease models of parkinsonism and Alzheimer’s disease (Chen et al., 2012; Nomura et al., 2011; Piro
et al., 2012). Despite these advances in our understanding of
eCB-eicosanoid crosstalk, how this interplay is enacted at the
cellular level in the nervous system remains unknown. We set
out to address this important question by first assessing the
integrity of the eCB-prostaglandin network in individual brain
cell types. Cultured neurons lacking MAGL showed significant
elevations in 2-AG and reductions in AA, but, interestingly, did
not produce detectable levels of prostaglandins (Figures 4A–
4C). In contrast, MAGL / astrocytes, while displaying a more
modest relative increase in 2-AG compared to neurons, proved
capable of translating their heightened eCB content into
corresponding reductions in AA and prostaglandins (Figures
4A–4C). These findings indicate that individual brain cell types,
despite expressing prostaglandin biosynthetic enzymes in
culture (Hewett et al., 2000; Ikeda-Matsuo et al., 2005), differ in
their capacity to autonomously convert eCBs to prostaglandins,
raising the possibility that this process involves transcellular
metabolism in vivo.
A broader analysis of brain lipids revealed that, as expected
based on previous studies (Nomura et al., 2011), global inactivation of MAGL not only elevated 2-AG but also lowered AA and
prostaglandins (Figure 4D). MAGL-TKO mice also displayed
markedly blunted induction of prostaglandin synthesis following
lipopolysaccharide (LPS) administration compared to their
MAGL+/+ littermates (Figure 4D). In contrast, MAGL-NKO mice,
despite showing 5-fold elevations in brain 2-AG, exhibited
negligible changes in AA or prostaglandin content under basal
conditions or following LPS treatment (Figure 4E). MAGL-AKO
mice, on the other hand, while exhibiting a more modest increase
in brain 2-AG (3-fold), showed significantly reduced brain AA
content and attenuated prostaglandin production following
LPS treatment (Figure 4F). Basal changes in brain prostaglandins
were not observed in MAGL-AKO mice and the magnitude of
decrease in these eicosanoids following LPS treatment was
less substantial than that observed in MAGL-TKO mice (Figures
4D and 4F).
LPS treatment, in addition to inducing brain prostaglandin
synthesis, stimulates an acute neuroinflammatory response as
reflected in microglial activation and cytokine production.
Consistent with previous findings, MAGL-TKO mice showed significant reductions in LPS-induced brain cytokines and microglial
activation compared to MAGL+/+ littermates (Figure S3A–S3D).
These neuroinflammatory markers were, however, not altered
in MAGL-NKO mice (Figures S3E–S3H). MAGL-AKO mice
showed an intermediate phenotype, with modest but significant
reductions in LPS-induced brain cytokine and unaltered microglial activation compared to MAGL+/+ mice (Figures S3I–S3L).
Consistent with the absence of changes in bulk brain lipids in
MAGL-MKO mice, these animals displayed no alterations in
LPS-induced prostaglandin and cytokines production or microglial activation (Figures S4A–S4D). We did find, however, that
cultured MAGL / microglia were impaired in producing prostaglandins and also displayed substantially reduced in vitro inflammatory responses (Figures S4E and S4F), consistent with recent
reports (Pihlaja et al., 2015). It is possible that incomplete removal

Figure 4. Astrocytes Hydrolyze 2-AG to Generate AA Precursor Pools for Pro-inflammatory Prostaglandin Production
(A–C) 2-AG (A), AA (B), and PGDE2/D2 (C) levels in MAGL+/+ and MAGL / neurons and astrocytes. N, neurons; A, astrocytes.; N.D., not detectable. n = 5 per cell
type and genotype. Error bars represent SEM; **p < 0.01 versus corresponding MAGL+/+ cells.
(D–F) Brain levels of 2-AG, AA, PGE2, and PGD2 in MAGL-TKO (D), MAGL-NKO (E), and MAGL-AKO (F) mice following administration of vehicle or LPS (20 mg/kg
intraperitoneally, 6 hr). n = 6–8 mice per genotype and treatment. Error bars represent SEM; *p < 0.05 and **p < 0.01 versus corresponding MAGL+/+ vehicle
treated; #p < 0.05 and ##p < 0.01 versus MAGL / vehicle treated; &p < 0.05 and &&p < 0.01 versus MAGL+/+ LPS treated.
See also Figures S3 and S4.

of MAGL from all brain microglia in the MAGL-MKO mice (Figure S1E) prevented observation of a contribution from microglia-derived MAGL to neuroinflammatory responses in vivo.
Taken together, our in vitro and in vivo data provide strong evidence that eCB-eicosanoid crosstalk depends on the coordinated metabolic activities of neurons and astrocytes, with the
former cell type providing robust production of 2-AG and the
latter possessing the capacity to convert this eCB into prostaglandins. As such, robust anti-neuroinflammatory effects were
only observed following global (versus cell-type-specific) deletion of MAGL, supporting a central role for neuronal-astrocytic
crosstalk in the regulation of eCB-eicosanoid networks in the
nervous system under pathological conditions.
Neuronal-Astrocytic Transcellular Shuttling of 2-AG and
Related Metabolites
Bidirectional shuttling of conventional neurotransmitters (e.g.,
glutamate and GABA) and their metabolic products between

neurons and glia is an established mechanism by which distinct
cellular pools of these chemical messengers and their signaling
activities can be regulated (Coulter and Eid, 2012). We postulated that 2-AG and/or 2-AG-derived metabolites might participate in a similar mode of intercellular transfer between neurons
and astrocytes, which could provide a mechanism to rebalance
bioactive lipid pools across these two cell types. To investigate
this possibility, we measured 2-AG and related metabolites in
MAGL+/+ and MAGL / neurons grown by themselves or cocultured with astrocytes in transwell dishes with polycarbonate
membrane-permeable supports, which permitted free exchange
of secreted metabolites in the absence of cell-cell contact. We
found that, when cultured alone, MAGL / neurons accumulated
and released higher amounts of 2-AG compared to MAGL+/+
neurons and experienced a corresponding depletion
in intracellular AA content (Figures 5A and 5B). In the presence
of MAGL+/+ astrocytes, however, MAGL / neurons showed
smaller relative elevations in intracellular and, especially,
Cell Reports 12, 798–808, August 4, 2015 ª2015 The Authors 803

Figure 5. Transcellular Shuttling of 2-AG
and AA between Neurons and Astrocytes
(A and B) Intracellular (A) and media (B) 2-AG and
AA levels from MAGL+/+ and MAGL / neurons
cultured alone ( ) or in the presence of astrocytes
(+) in transwell co-culture dishes. n = 5 per genotype. Error bars represent SEM; **p < 0.01 versus
MAGL+/+. ##p < 0.01 versus MAGL / neurons
cultured without astrocytes.
(C and D) Intracellular endogenous (gray bars) and
d8-labeled (black bars) 2-AG and AA levels from
MAGL+/+ and MAGL / neurons and MAGL+/+
astrocytes co-cultured together for 36 hr following
direct labeling of only one of the two cell types with
AA-d8. AA-d8 is readily incorporated into intracellular lipid pools of both neurons and astrocytes (C)
and is transferred to co-cultured cells that have
not themselves directly received AA-d8 (D). n = 5
per genotype. Error bars represent SEM; *p < 0.05
and **p < 0.01 versus corresponding MAGL+/+
cells.
(E) Endogenous and d8-labeled 2-AG and AA
levels in media from MAGL+/+ and MAGL /
neurons and MAGL+/+ astrocytes co-cultured
together for 36 hr following direct AA-d8 labeling of
only one of the two cell types. n = 5 per genotype.
Error bars represent SEM; **p < 0.01 versus corresponding MAGL+/+. ##p < 0.01 versus labeled
astrocytes.

secreted 2-AG, and attenuated reductions in intracellular AA
content (Figures 5A and 5B). Deletion of MAGL did not affect
secreted AA, although the absolute quantity of this lipid was
higher in the media of neuron/astrocyte co-cultures compared
to isolated neurons (neuron MAGL+/+ = 128 ± 89; neuron
MAGL / = 125 ± 12; co-culture MAGL+/+ astrocytes/MAGL+/+
neurons = 326 ± 19; co-culture MAGL+/+ astrocytes/MAGL /
neurons = 298 ± 43 pmol/mg protein; Figure 5B). Together, these
data indicated that astrocytes can take up 2-AG released from
neurons and may, in turn, deliver 2-AG-derived metabolites
(e.g., AA) back to neurons.
We next used metabolic labeling methods to examine in more
depth the bidirectional shuttling of AA-derived metabolites
between neurons and astrocytes. AA-d8 added to media was
readily incorporated into intracellular lipids of either neurons or
804 Cell Reports 12, 798–808, August 4, 2015 ª2015 The Authors

astrocytes in culture, including 2-AG
(2AG-d8) (Figure 5C) and other pools of
neutral lipids and phospholipids (e.g.,
18:0, 20:4 DAG-d8, 18:0, 20:4 PS-d8;
d8-labeled prostaglandins were not
detected, presumably due to their low
abundance; Figures S5A and S5B). AAd8-labeled astrocytes and neurons were
then co-cultured with ‘‘naı̈ve’’ neurons
or astrocytes, respectively, in transwell
dishes (36 hr co-culture; see Methods),
which resulted in extensive incorporation
of AA-d8 in the naive cells (Figures 5D,
S5C, and S5D). Examination of media
from these co-cultures revealed that
AA-d8-labeled neurons released higher amounts of 2AG-d8
compared to AA-d8-labeled astrocytes, which preferentially
secreted free AA-d8 (Figure 5E). Of note, AA-d8-labeled
MAGL / neurons accumulated and released more 2-AG-d8
than AA-d8-labeled MAGL+/+ neurons (Figures 5C and 5E),
resulting in higher uptake and metabolism of this eCB by neighboring ‘‘naı̈ve’’ astrocytes (Figures 5D and S5D). Even without
being directly labeled with AA-d8, MAGL–/– neurons also accumulated more 2-AG-d8 than MAGL+/+ neurons when co-cultured
with AA-d8-labeled MAGL+/+ astrocytes (Figure 5D). These data
thus provide evidence that transcellular shuttling from neurons to
astrocytes contributes to the metabolism of 2-AG, and,
conversely, astrocyte-derived AA can be returned to neurons
to rebalance the synthesis of arachidonoyl-containing lipids,
including 2-AG itself (Figure 6).

Figure 6. Distributed Oversight of 2-AG Metabolism and Function in
Neurons and Astrocytes
Proposed model of astrocytic-neuronal transcellular shuttling and metabolism
of 2-AG and AA. PIP2, phosphatidylinositol 4,5-biphosphate; PLC, phospholipase C; DAG, diacylglycerol; DAGLa, diacylglycerol lipase alpha; COX, cyclooxygenase.

DISCUSSION
Pharmacological or genetic disruption of MAGL produces profound changes in synaptic plasticity, neurophysiology, and
behavior (Blankman and Cravatt, 2013; Murataeva et al., 2014),
underscoring the substantive role played by 2-AG as a lipid
transmitter in the nervous system. Considering the diverse
signaling and metabolic functions of 2-AG, and that acute versus
chronic blockade of MAGL often results in opposing outcomes—
reflective of heightened 2-AG-mediated agonism and functional
antagonism of CB1Rs, respectively—it stands to reason that the
enzymatic termination of this eCB would be spatially and temporally organized in the nervous system to guard against excess
activity. One established mechanism to limit 2-AG action is the
positioning of MAGL at presynaptic terminals of neurons in close
proximity to CB1Rs (Straiker et al., 2009). Whether this subcellular distribution reflects a dominant role for neurons in the control
of 2-AG signaling capacity, however, remains unknown. By
leveraging a mouse line that imparts conditional deletion of
MAGL in specific brain cell types, we show that the metabolism
of 2-AG in vivo depends on both neurons and astrocytes and that
crosstalk between these cells modulates eCB-eicosanoid
signaling networks to affect synaptic plasticity, neuroinflammation, and neurobehavioral processes.
Some features of 2-AG metabolism and signaling were
affected to similar degrees by deletion of MAGL in neurons
and astrocytes. Selective loss of MAGL in neurons or astrocytes, for instance, comparably attenuated cerebellar DSE
and hippocampal DSI in comparison to MAGL-TKO mice, suggesting complementary roles for these cell types in terminating
retrograde 2-AG signaling. Our findings are also consistent with
a recent study showing that heterologous expression of MAGL
in Bergmann glia reverses the prolonged cerebellar DSE

observed in global MAGL / mice (Tanimura et al., 2012) and
extend this work in an important way by determining the function of endogenously expressed astrocytic MAGL in terminating
2-AG-mediated synaptic plasticity events in different brain regions. Perhaps most strikingly, we found that selective deletion
of MAGL in either neurons or astrocytes, despite producing significant elevations in brain 2-AG (5- and 3-fold, respectively),
averted the CB1R desensitization and behavioral tolerance
caused by global MAGL inactivation. The distributed metabolism of 2-AG across neurons and astrocytes thus protects
the nervous system from adaptive changes caused by excessive eCB signaling. In this manner, 2-AG metabolism appears
to differ from the cell-type-dominant inactivation observed for
more conventional neurotransmitters (e.g., astrocytes primarily
inactivate glutamate, while neurons mainly terminate GABA
signaling; Schousboe et al., 2013). We should further note that
the relative contributions of neuronal and astrocytic MAGL to
2-AG signal termination may differ at individual synapses, as
not all CB1R-positive nerve terminals express MAGL (Uchigashima et al., 2011).
Our studies also uncovered distinct and complementary roles
for neurons and astrocytes in 2-AG metabolism. MAGL deletion
in neurons caused a more dramatic cellular increase in 2-AG,
which was also efficiently secreted from these cells. Neurons
in culture, however, exhibited no detectable capacity to convert
2-AG to prostaglandins. Similarly, MAGL-NKO mice, despite
having substantially elevated brain 2-AG, did not show alterations in brain AA or prostaglandins under basal or neuroinflammatory conditions. Cultured astrocytes lacking MAGL, in
contrast, coupled elevations in 2-AG with reductions in AA
and prostaglandins. A similar lipid profile was observed for
LPS-treated MAGL-AKO mice. These data, taken together, indicate that astrocytes play a major role in facilitating eCB-eicosanoid crosstalk in the nervous system, where they appear to
convert both autonomously generated and neuronally derived
2-AG into AA and eicosanoids, especially under conditions of
neuroinflammation. While our studies did not provide evidence
that microglia contribute to brain eCB-eicosanoid crosstalk
in vivo, it is possible that bulk tissue measurements failed to
detect more anatomically or temporally restricted roles for microglia in regulating eCB-eicosanoid networks. Likewise, other
2-AG metabolic enzymes (e.g., hydrolases [ABHD6, ABHD12;
Blankman et al., 2007; Marrs et al., 2010] and oxygenases
[COX2; Rouzer and Marnett, 2008]), as well as distinct enzymatic pathways for generating eicosanoids (e.g., PLA2G4A)
(Burke and Dennis, 2009), constitute additional potential modes
for metabolic regulation of eCB-eicosanoid pathways in the
brain.
How might distinct pools of 2-AG in neurons and astrocytes
be coordinately regulated and balanced? Our transwell co-culture studies indicate that both 2-AG and AA can shuttle between
neurons and astrocytes, with neurons being the main producers
of extracellular 2-AG and astrocytes converting this eCB into AA
(and presumably AA-derived metabolites) that can be returned
to neurons. We therefore propose a model in which neuronal
2-AG is hydrolyzed not only at synaptic terminals but also
by neighboring astrocytes, which then transfer AA back to neurons to regenerate signaling pools of 2-AG (Figure 6). The
Cell Reports 12, 798–808, August 4, 2015 ª2015 The Authors 805

transcellular movement of 2-AG from neurons to astrocytes may
be required to couple eCB and eicosanoid pathways under
basal conditions in which selective deletion of MAGL in either
neurons or astrocytes did not alter brain prostaglandins. In the
context of neuroinflammation, however, some of the AA generated from autonomous and/or neuronal sources of 2-AG is diverted in astrocytes for prostaglandin synthesis (Figures 6 and
S5E). The transcellular movement of AA and AA-derived metabolites to facilitate eicosanoid synthesis has also been shown to
occur in select peripheral systems, such as between alveolar
epithelial cells and macrophages or platelets and neutrophils
(Folco and Murphy, 2006). Evidence has also accumulated to
support the existence of lipid-binding proteins that regulate, at
least in part, the uptake, transport, and release of 2-AG and
AA; however, the identities and precise contributions of these
proteins remain unclear (Brash, 2001; Fowler, 2013). Determining potential protein carriers and transporters that participate in neuron-astrocyte lipid shuttling represents a fertile topic
for future research. Our model further shares some organizational similarity with the glutamate-glutamine cycle, in which
synaptic glutamate is taken up by astrocytes, amidated into
glutamine, and transferred back to neurons for re-synthesis of
glutamate (Danbolt, 2001). Thus, neuron-astrocyte crosstalk appears to be a conserved mechanism for compartmentalizing
and regulating the functions of diverse synaptic modulators
that include both classical neurotransmitters and retrograde
lipid messengers.

Transwell Co-culture Studies
Neurons and astrocytes were co-cultured in 10-cm transwell dishes with polycarbonate membrane permeable supports for 16 days prior to organic extraction of lipids from each cell type separately. For AA-d8 labeling experiments,
membrane permeable supports from 12 DIV co-cultures were temporarily
transferred to a separate culture dish so that either neurons or astrocytes could
be labeled with AA-d8 conjugated to BSA (Rouzer et al., 2006). After 48 hr, cells
were thoroughly washed and returned to the original co-culture for another
36 hr prior to organic extraction of lipids from each cell type separately.
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For an extended section, see Supplemental Experimental Procedures.
Generation of Conditional MAGL / Mice
Mice carrying a loxP-flanked catalytic exon 4 Mgll allele for the conditional
ablation of MAGL were generated using standard gene-targeting techniques.
Homozygous MAGLloxP mice were bred to Rosa26-Cre (Otto et al., 2009),
Eno2-Cre (Frugier et al., 2000), GFAP-Cre (Tao et al., 2011), and LysM-Cre
mice (Clausen et al., 1999) to generate MAGL-TKO, MAGL-NKO, MAGLAKO, and MAGL-MKOs respectively.
Biochemical Studies
ABPP, substrate activity assays, and agonist-stimulated [35S]GTPgS binding
assays were performed as previously described (Schlosburg et al., 2010) using
cell membrane homogenates from 2-month-old conditional MAGL / mice
and wild-type littermates or from primary neurons, astrocytes, and microglia.
Electrophysiology
DSE at PF to PC synapses and DSI at CA1 pyramidal neuron synapses were
examined in cerebellar and hippocampal slices, respectively from MAGL+/+
or MAGL / mice from the different MAGL conditional lines as previously
described (Pan et al., 2009; Zhong et al., 2011).
Behavioral Assays
Two-month-old conditional MAGL / and wild-type littermates were evaluated for cannabimimetic responses (antinociception and hypothermia)
following injection with WIN55,212-2 using a cumulative dosing regimen as
described elsewhere (Schlosburg et al., 2010).
Liquid Chromatography-Mass Spectrometry Metabolite Profiling
Tissue lipid levels in 2-month-old MAGL+/+ or MAGL / mice from the different
MAGL conditional lines were measured from organic-soluble brain extracts by
targeted MRM methods (Nomura et al., 2011).
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Pacher, P., Bátkai, S., and Kunos, G. (2006). The endocannabinoid system as
an emerging target of pharmacotherapy. Pharmacol. Rev. 58, 389–462.
Pan, B., Wang, W., Long, J.Z., Sun, D., Hillard, C.J., Cravatt, B.F., and Liu, Q.S.
(2009). Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)
methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. J. Pharmacol. Exp. Ther. 331, 591–597.
Pan, B., Wang, W., Zhong, P., Blankman, J.L., Cravatt, B.F., and Liu, Q.S.
(2011). Alterations of endocannabinoid signaling, synaptic plasticity, learning,
and memory in monoacylglycerol lipase knock-out mice. J. Neurosci. 31,
13420–13430.
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